PrecisionLife Limited And Sano Genetics To Accelerate Genetics Understanding Of Long Covid-19

Biotechnology Healthcare

PrecisionLife Limited, a techbio company using the company’s deep insights into the disease biology and patient stratification for the purpose of driving the precision medicine in the chronic diseases, has announced a partnership with Sano Genetics, a genetic research platform enabling the patients for participating in the ethical research projects for advancing the understanding of the long-term enabling the patients for participating in the ethical research projects for advancing to understand the long-term effects of the novel corona virus infection.

The project is going to be including the analysis of the data of Sano Genetics from 3,000 adults of the United Kingdom suffering from the long corona virus symptoms by using the proprietary combinatorial analytics platform of PrecisionLife for identifying the potential drug targets and risk-factors.

It is also expected that, 5 percent to 30 percent of corona virus patients is going on to have a long-term complications and with more than 500 million across the world has confirmed as having been infected by the virus along with the need for better diagnostics and the treatments has also been large.

See also  US FDA Approves Roche’s COVID-19 Antibody Treatment

Dr Steve Gardner, chief executive officer of PrecisionLife said, they are confident that, this study or research on the long-term effects of the novel corona virus infection working the partnership with the Sano Genetics is going to be delivering the valuable insights for enabling a better understanding of the long corona virus.

Swati Jaiswal

Editor/Content Writer